Elanco Animal Health Incorporated Payments of Debt Issuance Costs
Elanco Animal Health Incorporated (ELAN) reported Payments of Debt Issuance Costs of $2.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2023-03-01
- Elanco Animal Health Incorporated payments of debt issuance costs for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Elanco Animal Health Incorporated payments of debt issuance costs for the quarter ending 2022-09-30 was $1.00M, a 0.00% change year-over-year.
- Elanco Animal Health Incorporated payments of debt issuance costs for the quarter ending 2021-12-31 was $1.00M.
- Elanco Animal Health Incorporated payments of debt issuance costs for the quarter ending 2021-09-30 was $1.00M, a 99.00% decline year-over-year.
- Elanco Animal Health Incorporated payments of debt issuance costs for fiscal 2022 was $2.00M, a 0.00% change from fiscal 2021.
- Elanco Animal Health Incorporated payments of debt issuance costs for fiscal 2021 was $2.00M, a 98.04% decline from fiscal 2020.
- Elanco Animal Health Incorporated payments of debt issuance costs for fiscal 2020 was $102.00M.
- Elanco Animal Health Incorporated payments of debt issuance costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 3 month as first filed | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 6 month as first filed | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 9 month as first filed | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.00M derived: sum of 2 quarters · filed 2023-03-01 | $2.00M 10-K · filed 2023-03-01 | |||||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.00M 10-Q · filed 2022-11-08 | ||||||
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-08 | |||||||
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.00M derived: sum of 2 quarters · filed 2023-03-01 | $2.00M derived: sum of 3 quarters · filed 2023-03-01 | $2.00M 10-K · filed 2023-03-01 | ||||
| 2021-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.00M derived: sum of 2 quarters · filed 2022-11-08 | $1.00M 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | -$1.00M derived: sum of 3 quarters · filed 2023-03-01 | $99.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | -$1.00M derived: sum of 2 quarters · filed 2023-03-01 | $99.00M derived: sum of 3 quarters · filed 2023-03-01 | $99.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $99.00M derived: sum of 2 quarters · filed 2023-03-01 | $99.00M derived: sum of 3 quarters · filed 2023-03-01 | $102.00M 10-K · filed 2023-03-01 | $102.50M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $100.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $100.00M derived: sum of 2 quarters · filed 2021-11-05 | $103.00M 10-Q · filed 2021-11-05 | $102.50M 10-Q · filed 2020-11-06 | $103.00M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.00M 10-Q · filed 2021-08-09 | $3.20M 10-Q · filed 2020-07-30 | $3.00M derived: sum of 3 quarters · filed 2022-02-28 | $3.00M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-07 | $3.10M 10-Q · filed 2020-05-07 | $3.00M derived: sum of 2 quarters · filed 2022-02-28 | $3.00M derived: sum of 3 quarters · filed 2022-02-28 | $3.00M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | |||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $0.00 10-Q · filed 2020-07-30 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $24.50M 10-K · filed 2021-03-01 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |